Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 76,890 shares, a decline of 90.2% from the January 31st total of 782,950 shares. Based on an average daily trading volume, of 188,271 shares, the short-interest ratio is currently 0.4 days.
Separately, Maxim Group reiterated a “buy” rating and issued a $10.00 price target (down from $18.00) on shares of Xtant Medical in a research report on Wednesday, February 14th.
In other Xtant Medical news, Director Orbimed Advisors Llc purchased 945,819 shares of the company’s stock in a transaction dated Wednesday, February 14th. The stock was bought at an average cost of $7.20 per share, for a total transaction of $6,809,896.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
An institutional investor recently raised its position in Xtant Medical stock. Renaissance Technologies LLC raised its position in shares of Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) by 145.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 291,892 shares of the medical device company’s stock after purchasing an additional 173,100 shares during the period. Renaissance Technologies LLC owned approximately 1.43% of Xtant Medical worth $167,000 at the end of the most recent reporting period.
Xtant Medical (NYSEAMERICAN:XTNT) traded up $1.49 during midday trading on Wednesday, hitting $8.20. 418,049 shares of the stock were exchanged, compared to its average volume of 62,802. Xtant Medical has a 52 week low of $3.96 and a 52 week high of $14.52. The firm has a market capitalization of $140.58, a P/E ratio of -0.34 and a beta of 0.19.
WARNING: “Short Interest in Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) Declines By 90.2%” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/15/short-interest-in-xtant-medical-holdings-inc-xtnt-declines-by-90-2.html.
Xtant Medical Company Profile
Xtant Medical Holdings, Inc, formerly Bacterin International Holdings, Inc, develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment.
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.